Our Medicines

Help Shape Patient Care

Below is a list of the medicines Lilly currently markets in Canada, the Product Monographs (a scientific document that describes the medication’s properties, claims, indications, conditions of use and safety information) and Consumer Information (Part 3 of the Product Monograph). User manuals for our devices are also available for download on this page.

Please note that Canadian laws and regulations limit the amount of information on our products that we can provide to the general public via our web site and/or by other means. We encourage consumers wishing to obtain more detailed information on our products to speak to their health care professional or to contact the Lilly Customer Response Centre at 1-888-545-5972.

For information related to drug shortages: please click here to access the Canadian Drug Shortage Database for current information on drug shortages in Canada.

The product information on this web site is intended for residents of Canada only.

Product Product Monograph Consumer Information User Manual Additional Information
Adcirca® (tadalafil)
Alimta® (pemetrexed)
AxironTM (testosterone topical solution, 2%)
Byetta® (exenatide injection) Please see Health Canada’s Drug Product Database website for the current Byetta® product monograph. Byetta® is now owned by Bristol-Myers Squibb Canada, and is co-promoted by Bristol-Myers Squibb Canada and AstraZeneca Canada Inc.
Cialis® (tadalafil) Health Care Professional Letter
(June 2006)
Public Communication
(June 2006)
Cymbalta® (duloxetine hydrochloride) Health Care Professional Letter (January 2008)
Effient® (prasugrel hydrochloride) Health Care Professional Letter (January 2014)
Public Communication (January 2014)
Evista® (raloxifene hydrochloride) Health Care Professional Letter
(May 2006)
Public Communication
(May 2006)
Forteo® (teriparatide (rDNA origin) injection) Forteo® 2.4 mL Pen
Gemzar® (gemcitabine hydrochloride)
Glucagon (glucagon for injection, rDNA origin)
Humalog® (insulin lispro for injection)

Humalog® Mix25® (25% insulin lispro injection, 75% insulin lispro protamine suspension)

Humalog Mix50® (50% insulin lispro injection, insulin lispro protamine suspension)
Humalog® KwikPen®

Humalog® / Humalog® Mix25® Pre-filled Pen†
Humatrope® (somatropin for injection) HumatroPen®6 mg

HumatroPen®12 mg

HumatroPen®24 mg

Hidden Needle Cover User Manual
Humulin® (insulin, human biosynthetic)

Humulin® N (insulin isophane (rDNA origin)) NPH

Humulin® R (insulin injection (rDNA origin)) Regular

Humulin® 30/70 (30% insulin injection, 70% insulin isophane (rDNA origin))
Humulin® N Cartridges and KwikPen®

Humulin® N Vials

Humulin® R Cartridges and KwikPen®

Humulin® R Vials

Humulin® 30/70 Cartridges

Humulin® 30/70 Vials
Humulin® N and Humulin® R KwikPen®
JentaduetoTM (linagliptin/metformin HCl tablets)
Prozac® (fluoxetine hydrochloride) Health Care Professional Letter
(May 2004)
Reopro® (abciximab)
Strattera® (atomoxetine) Health Care Professional Letter
(Oct 2011)
Health Care Professional Letter
(May 2006)
Health Care Professional Letter
(Sept 2005)
Health Care Professional Letter
(Feb 2005)

Public Communication
(Oct 2011)
Public Communication
(May 2006)
Public Communication
(Sept 2005)
Public Communication
(Feb 2005)
Trajenta® (linagliptin)
Xigris® (drotrecogin alpha (activated)) Discontinued/Withdrawn Health Care Professional Letter
(Oct 2011)
Notice to Hospitals
(Oct 2011)
Public Communication (Oct 2011)
Zyprexa® (olanzapine)

Zyprexa® Zydis®*

Zyprexa® IntraMuscular (olanzapine tartrate for injection
Health Care Professional Letter
(Mar 2004)
Public Communication
(Mar 2004)

User Manuals for Re-useable Devices to be used with Humalog® and Humulin® family of products
HumaPen® Luxura®
HumaPen® Luxura® HD
HumaPen® Memoir®
HumaPen® Memoir® Quick Guide
HumaPen® SavvioTM

†Discontinued Device

*Important Note: You must have Acrobat Reader version 4.0 or higher installed to view these files. If you have an earlier version installed, an update is available from the Adobe Acrobat Reader download site.

® Registered trademark owned by Eli Lilly and Company; used under license. TM Trademark owned by Eli Lilly and Company; used under license.
®*Zydis is a trademark owned by R.P. Scherer Technologies, Inc., a Catalent Pharma Solutions Company.
Trajenta® is a trademark used under license by Boehringer Ingelheim (Canada) Ltd.  It’s co-promoted with Eli Lilly Canada Inc.

Lilly Canada is committed to diverting expired and/or unused health products from landfills and sewers, and ensuring their safe and effective collection and disposal. We are a member of the Health Products Stewardship Association.
Don’t throw them out, visit www.medicationsreturn.ca